Tuparstobart

DB19118InvestigationalProtein Based Therapies

Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS ≥ 1) Recurrent/metastatic Squamous Cell...

Mechanism: Pharmacologically active on Lymphocyte activation gene 3 protein
Curator reviewed
Also known as: Anti-LAG-3 Monoclonal Antibody INCAGN02385 · gamma1 heavy chain humanized (1-450) [VH (Homo sapiens IGHV1-46*02 (80.4%)-(IGHD) -IGHJ4*01 (100%), CDR-IMGT[8.8.14] (26-33.51-58.97-110)) (1-121)-Homo sapiens IGHG1*03, G1m3, nG1m1, G1v29 CH2 A84.4 (CH1 R120 (218) (122-219), hinge 1-15 (220-234), CH2 N8 · Immunoglobulin G1 [301-alanine,de-C-terminal-lysine], anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal INCAGN02385 γ1-chain), disulfide with human-Mus musculus monoclonal INCAGN02385 κ-chain, dimer · immunoglobulin G1-kappa,anti-[Homo sapiens LAG3 (lymphocyte activating 3, lymphocyte-activation 3, CD223)], humanized monoclonal antibody
Code names: AGEN-2385 · INCAGN-02385 · INCAGN 2385

Resolves to

Compound

UNIIZ0A08C63DFCAS2649466-03-3

Targets

P18627LAG3

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tuparstobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account